New York, NY, USA I February 26, 2024 I Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that it will present positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R), in patients with high IGF-1R tumor expression at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).
Lirum’s presentation “LX-101, a novel, clinical-stage, payload-bearing IGF-1R targeted therapy demonstrates activity in patients with high IGF-1R tumor expression” will be presented in the Hall Bordeaux at the Palais des Congrès. The poster presentation covers patient outcomes in the previous Phase 1a studies with LX-101, with a focus on those patients that we determined to have high IGF-1R tumor expression. Of the 19 patients treated with LX-101, 4 were considered high IGF-1R expressers. Of these 4 patients, 3 were evaluable for response, and 2/3 (67%) of these patients experienced disease control/response, including the one patient who had an objective response at the highest dose. The poster presentation is available on the Lirum website (www.lirumtx.com) under the Investors and Media tab.
Given the promising results, including that patients with high IGF-1R expressing tumors can be clinically sensitive to LX-101, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway. Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.
About Lirum Therapeutics, Inc.
Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum’s lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor-1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit www.lirumtx.com.
SOURCE: LirumTherapeutics
Post Views: 813
New York, NY, USA I February 26, 2024 I Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that it will present positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R), in patients with high IGF-1R tumor expression at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).
Lirum’s presentation “LX-101, a novel, clinical-stage, payload-bearing IGF-1R targeted therapy demonstrates activity in patients with high IGF-1R tumor expression” will be presented in the Hall Bordeaux at the Palais des Congrès. The poster presentation covers patient outcomes in the previous Phase 1a studies with LX-101, with a focus on those patients that we determined to have high IGF-1R tumor expression. Of the 19 patients treated with LX-101, 4 were considered high IGF-1R expressers. Of these 4 patients, 3 were evaluable for response, and 2/3 (67%) of these patients experienced disease control/response, including the one patient who had an objective response at the highest dose. The poster presentation is available on the Lirum website (www.lirumtx.com) under the Investors and Media tab.
Given the promising results, including that patients with high IGF-1R expressing tumors can be clinically sensitive to LX-101, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway. Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.
About Lirum Therapeutics, Inc.
Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum’s lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor-1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit www.lirumtx.com.
SOURCE: LirumTherapeutics
Post Views: 813
